| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| enoblituzumab | b7 homolog 3 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Malignant neoplasm of prostate[MeSHID:D011471] |
190.95 | phase 2 | antibody |
| enoblituzumab | b7 homolog 3 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Malignant neoplasm of prostate[MeSHID:D011471] |
190.95 | phase 2 | unknown |
| click here to return to the previous page | ||||||||